EW
Edwards Lifesciences Corporation
Stock
$85.15−0.04 (−0.05%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.7B | $1.6B | $542M | $896M | $1.2B | $1.7B | $1.1B | $1.2B | $927M | $1.0B | $704M | $550M | $1.0B | $473M | $362M | $308M | $251M | $165M | $153M |
| Capital expenditures | $287M | $260M | $252M | $253M | $245M | $326M | $407M | $254M | $239M | $168M | $176M | $103M | $83M | $109M | $109M | $77M | $62M | $64M | $51M |
| Free cash flow | $1.4B | $1.3B | $290M | $643M | $974M | $1.4B | $647M | $929M | $688M | $833M | $528M | $447M | $939M | $364M | $253M | $232M | $190M | $101M | $103M |
| Stock-based compensation | $168M | $158M | $162M | $139M | $127M | $109M | $93M | $81M | $71M | $62M | $57M | $50M | $48M | $47M | $42M | $35M | $29M | $28M | $29M |
| Buybacks | $1.2B | $893M | $1.2B | $880M | $1.7B | $513M | $625M | $263M | $796M | $763M | $662M | $280M | $301M | $497M | $344M | $303M | $200M | $96M | $307M |
| Free cash flow margin | 22.0% | 22.0% | 5.3% | 12.8% | 21.8% | 26.9% | 14.8% | 21.4% | 18.5% | 24.2% | 17.8% | 17.9% | 40.4% | 17.8% | 13.3% | 13.8% | 13.1% | 7.7% | 8.3% |